Novartis Oncology have issued a letter alerting healthcare providers of new safety information, including a boxed warning, for Exjade

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1290, 2010-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novartis have issued a 'Dear Healthcare Professional' letter announcing the association of daptomycin [Cubicin] with pulmonary eosinophilia.

By  

Reactions Weekly, Vol. 1, Iss. 1338, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Eli Lilly has issued a `Dear Healthcare Professional' letter to advise of a new warning on the US Xigris [drotrecogin alfa] label

By  

Reactions Weekly, Vol. 1, Iss. 1044-1045, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Novartis advises of updated prescribing information for Exjade

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Health Canada has issued both a Public Communication and a `Dear Healthcare Professional' letter advising of updated safety information for Invirase [saquinavir]

By  

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Safety information on gadodiamide issued in Canada

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite